Cue Biopharma, Inc.
CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$23.98
Price-2.56%
-$0.63
1Y
Price
Market Cap
$63.018m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-74.7%
EBITDA Margin-91.1%
Net Profit Margin-194.6%
Free Cash Flow Margin-74.7%
EBITDA Margin-91.1%
Net Profit Margin-194.6%
Free Cash Flow MarginRevenue
$32.731m
+19.2%
1y CAGR+94.7%
3y CAGR+156.3%
5y CAGREarnings
-$19.523m
+26.6%
1y CAGR+27.0%
3y CAGR+21.3%
5y CAGREPS
-$5.53
+34.2%
1y CAGR+43.5%
3y CAGR+39.0%
5y CAGRBook Value
$21.608m
$30.877m
Assets$9.269m
Liabilities$3.440m
DebtDebt to Assets
11.1%
-0.2x
Debt to EBITDAFree Cash Flow
-$24.605m
-12.5%
1y CAGR+12.1%
3y CAGR+10.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company